Beta
Back to IBRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

IBRX Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

Immunitybio, inc. (IBRX) 2025Q4 financial report shows revenue of 38.28M USD, with a YoY growth rate of 406.95%. This outstanding figure clearly proves the company’s exceptionally strong operational momentum and significant expansion in market demand. To accurately capture Immunitybio, inc. (IBRX)’s future growth potential, investors should closely follow subsequent financial reports and key strategic movements, and deeply integrate diversified data and tools such as Growin AI Value Analysis for a comprehensive and forward-looking strategic assessment.